RC48‐ADC is a novel HER2‐targeting antibody‐drug conjugate (ADC) that selectively delivers the cytotoxic agent monomethyl auristatin E (MMAE) to HER2‐positive tumor cells. This evidence concerns the gene ERBB2 and neoplasm.